Adults 18 to 65, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Mean Change From Baseline in Pruritus Symptoms, as Measured by the 24-hour Average Pruritus Visual Analogue Scale (VAS) ScorePrimary· 56 days
Responses were measured on a 100-mm Visual Analogue Scale (VAS), where the left endpoint was marked "no itch" (0 mm) and in the right endpoint was marked "worst imaginable itch" (100 mm).
Group
Value
95% CI
Tradipitant
-41.5
± 3.89
Placebo
-35.8
± 4.03
Adverse events — posted to ClinicalTrials.gov
Time frame: All Adverse Events (AEs) were collected from signature of the informed consent through study completion (approximately 100 days) regardless of seriousness or relationship to investigational product..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07446439 — A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
· Phase 3
· recruiting
NCT06804603 — A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
· Phase 2
· completed
NCT05903924 — Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
· Phase 3
· completed
NCT06138613 — Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
· Phase 3
· active not recruiting
NCT04327661 — Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
· Phase 3
· completed
Other recruiting trials for Atopic Dermatitis
Currently open trials in the same condition.
NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi
· Phase 1
· recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis
· Phase 2
· recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants
· Phase 1
· recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit
· recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E
· Phase 1
· recruiting
Other Vanda Pharmaceuticals trials
Trials by the same sponsor.
NCT07446439 — A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
· Phase 3
· recruiting
NCT06804603 — A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
· Phase 2
· completed
NCT06701396 — Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant
· Phase 3
· recruiting
NCT06494397 — Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
· Phase 1
· completed
NCT05903924 — Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
· Phase 3
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanda Pharmaceuticals
Last refreshed: 13 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02651714.